First Tracks Biotherapeutics, Inc. TRAX
50.53 USD -1.80 (-3.44%)
At closeNov 11, 2026, 6:15 PM EST
51.54 +1.01 +2.00%
After hours · Nov 11, 6:15 PM ET
49.57 Day range 53.75
14.72 52-week range 54.78
- YTD
- +165.95%
- 1 year
- +165.95%
News
benzinga.com Guggenheim Maintains Buy on First Tracks, Raises Price Target to $110 Guggenheim analyst Yatin Suneja maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $100 to $110.
globenewswire.com First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
globenewswire.com First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
benzinga.com Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90 Leerink Partners analyst David Risinger maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $70 to $90.
benzinga.com First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory…
globenewswire.com First Tracks Biotherapeutics Announces $200 Million Private Placement SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
seekingalpha.com First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease with statistically significant histology and symptom improvements.…- benzinga.com Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60 Canaccord Genuity analyst Edward Nash maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $50 to $60.
benzinga.com Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70 Evercore ISI Group analyst Gavin Clark-Gartner maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $65 to $70.- benzinga.com Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $70 Wells Fargo analyst Derek Archila maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $62 to $70.
defenseworld.net First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals First Tracks Biotherapeutics (NASDAQ: TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met…
marketbeat.com First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals First Tracks Biotherapeutics NASDAQ: TRAX reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic…
benzinga.com Dow Gains Over 200 Points; Chipotle Shares Move Lower U.S. stocks traded mixed: Dow rose 0.47%, S&P 500 edged up, Nasdaq fell; energy led gains, while Chipotle dropped after Starbucks denied takeover rumors.
benzinga.com First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Monday.
benzinga.com First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday U.S. stocks mixed; First Tracks Biotherapeutics surged 18% on positive celiac trial results, while C3.ai, Liquidia and others also gained.
benzinga.com Stock Market Today: S&P 500, Dow Futures Gain, Nasdaq 100 Falls as Iran Flags ‘Inadequate’ US Response to Peace Terms — SMP, QMCO, SVRN in Focus (UPDATED) U.S. stock futures were mixed on Monday, as the Dow Jones and S&P 500 indices rose, while the Nasdaq 100 index fell.
benzinga.com Why Is First Tracks Biotherapeutics Stock Soaring Monday? First Tracks Biotherapeutics (TRAX) stock surged 13% on positive Phase 1b celiac disease trial results for ANB033. Read the update.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million. DataMEDS AI…- benzinga.com First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on…
benzinga.com Why J-Star Holding Shares Are Trading Higher By Around 128%; Here Are 20 Stocks Moving Premarket J-Star Holding surged 127.9% premarket after funding U.S. drone-frame expansion; Linkers and VCI gained, while Vivakor and China SXT fell.
globenewswire.com First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
benzinga.com Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50 Canaccord Genuity analyst Edward Nash initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $50.
benzinga.com This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.- benzinga.com Evercore ISI Group Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $65 Evercore ISI Group initiates coverage on First Tracks (NASDAQ:TRAX) with a Outperform rating and announces Price Target of $65.
- benzinga.com Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100 Guggenheim analyst Yatin Suneja initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $100.
defenseworld.net Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) Director J. Anthony Ware sold 39,265 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an…- benzinga.com HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $57 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates First Tracks (NASDAQ:TRAX) with a Buy and maintains $57 price target.
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
globenewswire.com First Tracks Biotherapeutics Announces Participation in September Investor Conferences SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways…- benzinga.com Barclays Maintains Overweight on First Tracks, Raises Price Target to $65 Barclays analyst Etzer Darout maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $48 to $65.
benzinga.com First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.
benzinga.com First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.
benzinga.com Wedbush Maintains Outperform on First Tracks, Raises Price Target to $70 Wedbush analyst Martin Fan maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $60 to $70.- benzinga.com Piper Sandler Maintains Overweight on First Tracks, Raises Price Target to $95 Piper Sandler analyst Yasmeen Rahimi maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $54 to $95.
benzinga.com Brinker International To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday Top analysts changed outlook on top names. Truist, Morgan Stanley, B of A Securities, HC Wainwright, Baird, and Stephens & Co. altered price targets for various stocks.- benzinga.com HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $57 HC Wainwright & Co. analyst Emily Bodnar maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $44 to $57.
- benzinga.com First Tracks Q2 EPS $(0.95) Up From $(1.47) YoY First Tracks (NASDAQ:TRAX) reported quarterly losses of $(0.95) per share. This is a 35.37 percent increase over losses of $(1.47) per share from the same period last year.
globenewswire.com First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
benzinga.com UBS Maintains Buy on First Tracks, Raises Price Target to $65 UBS analyst Michael Yee maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $45 to $65.- benzinga.com Wedbush Maintains Outperform on First Tracks, Raises Price Target to $60 Wedbush analyst Martin Fan maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $30 to $60.
- benzinga.com Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $55 Wells Fargo analyst Derek Archila maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $30 to $55.
benzinga.com Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and technology order. Other big gainers include NIPG, FBRX, TRAX, GENI, BMNR, OMER, ASAN, EIKN, IONQ, and…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Niki BioSolutions (NASDAQ:NIKI) stock moved upwards by 44.7% to $13.01 during Thursday's pre-market session. The company's market cap stands at $73.2 million. Zhengye Biotechnology…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals…
benzinga.com Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guidance. Other gainers: UTZ, AEHR, PKE, FWRD, HELP, SECZ, DOCN, TRAX, PVLA, COIN.- benzinga.com Barclays Maintains Overweight on First Tracks, Raises Price Target to $48 Barclays analyst Etzer Darout maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $40 to $48.
defenseworld.net First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analysts Shares of First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the stock,…- benzinga.com HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $44 HC Wainwright & Co. analyst Emily Bodnar maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $30 to $44.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences…